FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079809618> ?p ?o ?g. }

• W2079809618 endingPage "1013" @default.
• W2079809618 startingPage "1002" @default.
• W2079809618 abstract "The safety of cell therapy applications can be enhanced by the introduction of Cell Fate Control (CFC) elements, which encode pharmacologically controlled cellular suicide switches. CFC Gene Therapy (CFCGT) offers the possibility of establishing control over gene-modified cells (GMCs) with regards to their proliferation, differentiation, or function. However, enzymes commonly employed in these approaches often possess poor kinetics and high immunogenicity. We describe a novel CFCGT system based on engineered variants of human deoxyCytidine Kinase (dCK) that overcomes limitations of current modalities. Mutants of dCK with rationally designed active sites that make them thymidine-activating were stably introduced into cells by recombinant lentiviral vectors (LVs). Transduced cells maintained growth kinetics and function. These dCK mutants efficiently activate bromovinyl-deoxyuridine (BVdU), l-deoxythymidine (LdT), and l-deoxyuridine (LdU), which are otherwise not toxic to wild-type cells. We show that mutant dCK-expressing Jurkat, Molt-4, and U87mg cells could be efficiently eliminated in vitro and in xenogeneic leukemia and tumor models in vivo. We also describe a fusion construct of the thymidine-activating dCK to the cytoplasmic tail-truncated LNGFR molecule and applications to in vivo eradication of primary human T cells. This novel CFCGT system offers unique plasticity with respect to the wide range of prodrugs it can potentiate, and can be used as a reliable safety switch in cell and gene therapy. The safety of cell therapy applications can be enhanced by the introduction of Cell Fate Control (CFC) elements, which encode pharmacologically controlled cellular suicide switches. CFC Gene Therapy (CFCGT) offers the possibility of establishing control over gene-modified cells (GMCs) with regards to their proliferation, differentiation, or function. However, enzymes commonly employed in these approaches often possess poor kinetics and high immunogenicity. We describe a novel CFCGT system based on engineered variants of human deoxyCytidine Kinase (dCK) that overcomes limitations of current modalities. Mutants of dCK with rationally designed active sites that make them thymidine-activating were stably introduced into cells by recombinant lentiviral vectors (LVs). Transduced cells maintained growth kinetics and function. These dCK mutants efficiently activate bromovinyl-deoxyuridine (BVdU), l-deoxythymidine (LdT), and l-deoxyuridine (LdU), which are otherwise not toxic to wild-type cells. We show that mutant dCK-expressing Jurkat, Molt-4, and U87mg cells could be efficiently eliminated in vitro and in xenogeneic leukemia and tumor models in vivo. We also describe a fusion construct of the thymidine-activating dCK to the cytoplasmic tail-truncated LNGFR molecule and applications to in vivo eradication of primary human T cells. This novel CFCGT system offers unique plasticity with respect to the wide range of prodrugs it can potentiate, and can be used as a reliable safety switch in cell and gene therapy." @default.
• W2079809618 created "2016-06-24" @default.
• W2079809618 creator A5018841168 @default.
• W2079809618 creator A5024793393 @default.
• W2079809618 creator A5033158463 @default.
• W2079809618 creator A5042486255 @default.
• W2079809618 creator A5057696298 @default.
• W2079809618 creator A5074220802 @default.
• W2079809618 date "2012-05-01" @default.
• W2079809618 modified "2023-09-23" @default.
• W2079809618 title "Cell Fate Control Gene Therapy Based on Engineered Variants of Human Deoxycytidine Kinase" @default.
• W2079809618 cites W1971370951 @default.
• W2079809618 cites W1975255631 @default.
• W2079809618 cites W1975703199 @default.
• W2079809618 cites W1977202875 @default.
• W2079809618 cites W1979921359 @default.
• W2079809618 cites W1981452400 @default.
• W2079809618 cites W1986156788 @default.
• W2079809618 cites W1987746867 @default.
• W2079809618 cites W1988450448 @default.
• W2079809618 cites W1998609613 @default.
• W2079809618 cites W2002040141 @default.
• W2079809618 cites W2005447841 @default.
• W2079809618 cites W2012562524 @default.
• W2079809618 cites W2016669226 @default.
• W2079809618 cites W2017023187 @default.
• W2079809618 cites W2017304478 @default.
• W2079809618 cites W2024823372 @default.
• W2079809618 cites W2025725704 @default.
• W2079809618 cites W2025937740 @default.
• W2079809618 cites W2026599178 @default.
• W2079809618 cites W2035311687 @default.
• W2079809618 cites W2037220161 @default.
• W2079809618 cites W2040523278 @default.
• W2079809618 cites W2045098550 @default.
• W2079809618 cites W2047199050 @default.
• W2079809618 cites W2052723048 @default.
• W2079809618 cites W2059730196 @default.
• W2079809618 cites W2062179993 @default.
• W2079809618 cites W2066334259 @default.
• W2079809618 cites W2066336622 @default.
• W2079809618 cites W2067016959 @default.
• W2079809618 cites W2071712084 @default.
• W2079809618 cites W2073864860 @default.
• W2079809618 cites W2084574751 @default.
• W2079809618 cites W2092175635 @default.
• W2079809618 cites W2094337481 @default.
• W2079809618 cites W2097175022 @default.
• W2079809618 cites W2105308429 @default.
• W2079809618 cites W2121197776 @default.
• W2079809618 cites W2122465970 @default.
• W2079809618 cites W2122886000 @default.
• W2079809618 cites W2123610775 @default.
• W2079809618 cites W2126764647 @default.
• W2079809618 cites W2134652893 @default.
• W2079809618 cites W2143693981 @default.
• W2079809618 cites W2149033728 @default.
• W2079809618 cites W2157777129 @default.
• W2079809618 cites W2160438188 @default.
• W2079809618 cites W2171653261 @default.
• W2079809618 doi "https://doi.org/10.1038/mt.2011.298" @default.
• W2079809618 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3345984" @default.
• W2079809618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22273576" @default.
• W2079809618 hasPublicationYear "2012" @default.
• W2079809618 type Work @default.
• W2079809618 sameAs 2079809618 @default.
• W2079809618 citedByCount "18" @default.
• W2079809618 countsByYear W20798096182012 @default.
• W2079809618 countsByYear W20798096182013 @default.
• W2079809618 countsByYear W20798096182015 @default.
• W2079809618 countsByYear W20798096182016 @default.
• W2079809618 countsByYear W20798096182017 @default.
• W2079809618 countsByYear W20798096182018 @default.
• W2079809618 countsByYear W20798096182019 @default.
• W2079809618 countsByYear W20798096182021 @default.
• W2079809618 countsByYear W20798096182022 @default.
• W2079809618 crossrefType "journal-article" @default.
• W2079809618 hasAuthorship W2079809618A5018841168 @default.
• W2079809618 hasAuthorship W2079809618A5024793393 @default.
• W2079809618 hasAuthorship W2079809618A5033158463 @default.
• W2079809618 hasAuthorship W2079809618A5042486255 @default.
• W2079809618 hasAuthorship W2079809618A5057696298 @default.
• W2079809618 hasAuthorship W2079809618A5074220802 @default.
• W2079809618 hasBestOaLocation W20798096181 @default.
• W2079809618 hasConcept C104317684 @default.
• W2079809618 hasConcept C111599444 @default.
• W2079809618 hasConcept C121608353 @default.
• W2079809618 hasConcept C2522874641 @default.
• W2079809618 hasConcept C2776147627 @default.
• W2079809618 hasConcept C2777844706 @default.
• W2079809618 hasConcept C2779268695 @default.
• W2079809618 hasConcept C2780258809 @default.
• W2079809618 hasConcept C2781196997 @default.
• W2079809618 hasConcept C34981463 @default.
• W2079809618 hasConcept C502942594 @default.
• W2079809618 hasConcept C54355233 @default.
• W2079809618 hasConcept C86803240 @default.
• W2079809618 hasConcept C95444343 @default.

• next